

Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B

#R00103

Size: 5 µg/100 µg/500 µg

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.



Warning: This product is intended for scientific research only. It is not to be used for medical or diagnostic procedures in humans or animals, nor as a food, cosmetic, or household product.

AA Sequence

MPAQVAFTPYAPEGSTCRLREYYDQTAQMCCSKCS
PGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPEC
LSCGSRCSSDQVETQACTREQNRICTCRPGWYCAL
SKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKP
CAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVC
TSTSPT

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Product Specification

Accession	P20333
GeneID	7133
Species	Human
Source	Escherichia coli.
Molecular Weight	Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids.
Purity	> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity	Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the

	presence of 0.25 ng/mL of rHuTNF-α.
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.
Endotoxin	Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.